Article Details

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA ...

Retrieved on: 2024-10-27 00:17:46

Tags for this article:

Click the tags to see associated articles and topics

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA .... View article details on hiswai:

Excerpt

Felzartamab, an investigational anti-CD38 monoclonal antibody, selectively reduced IgA antibody levels while maintaining IgG and IgM levels. The ...

Article found on: www.stocktitan.net

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo